ERBB2 and brain neoplasm: To evaluate 2Rs15d’s added value as a theranostic radiopharmaceutical and potential advantage over trastuzumab for difficult-to-treat brain tumors, two HER2-overexpressing cell lines were used, one sensitive and one resistant to trastuzumab as demonstrated in vitro.